RecruitingPHASE1, PHASE2NCT04464759
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Studying Lysosomal disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ravi Amaravadi, MD
- Principal Investigator
- Ravi Amaravadi, MDAbramson Cancer Center at Penn Medicine
- Intervention
- Nivolumab(drug)
- Enrollment
- 94 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2027
Study locations (1)
- Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania, United States
Collaborators
Bristol-Myers Squibb
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04464759 on ClinicalTrials.govOther trials for Lysosomal disease
Additional recruiting or active studies for the same condition.